Kadmon Corporation, LLC

Xuemei Yu

Kevin G Liu

Ji-In Kim

Masha V Poyurovsky

Koi Morris

Kellen L Olszewski

Anthony Michael Barsotti

Christophe Lamarque

This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.

Glucose uptake inhibitors

This invention provides methods of treating inflammatory conditions and autoimmune diseases in a mammal, comprising administering to the mammalian subject in need thereof a therapeutically effective amount of a compound, or pro-drug thereof, or pharmaceutically acceptable salt or ester of said compound or pro-drug, wherein the compound is an inhibitor of glucose uptake. In particular aspects, the present invention provides a method of treating inflammatory conditions and autoimmune diseases in a mammal, and preferably a human, in which the glucose uptake inhibitor modulates the glucose transport of GLUT1 and GLUT3.

Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors

Growing community of inventors

Livingston, NJ, United States of America

Xuemei Yu